Pembrolizumab与多西紫杉醇在晚期经治PD-L1阳性非小细胞肺癌患者中的疗效比较

Compare the Curative Effect of Pembrolizumab and Docetaxel for Previously Treated PD-L1-Positive Advanced Non-Small Cell Lung Cancer

1文献来源Herbst RS,Baas P,Kim DW,et al.Pembrolizumab versus Docetaxel for previouslytreated,PD-L1-positive,advanced non-small-cell lungcancer（KEYNOTE-010）：A randomised controlledtrial[J].Lancet,2016,387（10027）：1540-1550.2证据水平1b。